Trulieve Lists on NYSE, Competes with Tilray
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: NASDAQ.COM
- Listing Achievement: Trulieve began trading on the NYSE on June 10, becoming the first U.S. cannabis company to list on a major exchange, marking a significant milestone for the U.S. cannabis industry and potentially attracting more investor interest.
- Financial Performance Comparison: Trulieve reported $100 million in adjusted EBITDA for Q1, while Tilray expects EBITDA between $62 million and $72 million this year, highlighting Trulieve's clear advantage in profitability.
- Market Competition Landscape: With 240 dispensaries, Trulieve's operational model allows it to capture the entire retail markup, whereas Tilray, primarily a wholesale manufacturer, faces greater pricing pressure, resulting in significantly lower profit margins compared to Trulieve.
- Tax Policy Impact: The U.S. reclassification of medical marijuana to Schedule III alleviates Trulieve's 280E tax burden, which is expected to yield substantial financial benefits, further solidifying its leadership position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 5.120
Low
8.50
Averages
9.57
High
10.00
Current: 5.120
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. Its adult-use portfolio offers a range of products, from flowers to beverages. Its beverage-alcohol portfolio includes a selection of craft beer, spirits, and beverages.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Reports 73% Revenue Growth in International Cannabis Business
- Revenue Growth Highlight: Tilray reported $206.7 million in sales for Q3 2026, marking a 73% increase, yet its international cannabis segment only contributes 12% to total sales, indicating a still limited market share.
- Ongoing Loss Risk: Despite revenue growth, Tilray has consistently lost money since going public, with a market cap around $600 million, suggesting that this stock remains a high-risk investment suitable only for aggressive investors.
- Business Transformation Strategy: Tilray is undergoing a significant business overhaul, shifting from a pure-play cannabis company to a global lifestyle and consumer packaged goods firm, though this strategy's sustainability remains to be seen.
- Market Challenges and Opportunities: While international cannabis sales show strength, a 24% decline in beverage sales and a 20% drop in U.S. operations highlight challenges the company faces, necessitating cautious evaluation of its overall business health.
See More
Tilray Transitions to Brand Management Model
- International Growth: Tilray's international cannabis business reported a 73% revenue increase in Q3 2026, totaling $24 million, which, while only 12% of total sales, indicates potential in international markets.
- Overall Sales Performance: The company generated $206.7 million in total sales for the quarter, a significant figure, yet with a market cap of approximately $600 million, it remains a small player, highlighting its fragile market position.
- Ongoing Losses: Tilray has consistently reported losses since going public, and despite its business model shift, the high-risk nature of the stock suggests that most investors should approach with caution until profitability is achieved.
- Transformation Challenges: The shift from a pure cannabis business to a global lifestyle and consumer packaged goods company has seen some successes, yet the beverage segment experienced a 24% sales decline, underscoring the uncertainties and challenges in the transformation process.
See More
Trulieve Becomes First U.S. Cannabis Company Listed on NYSE
- Historic Listing: Trulieve successfully listed on the NYSE on June 10, becoming the first U.S. cannabis company on a major exchange, marking a significant milestone for the U.S. cannabis industry and likely attracting increased investor interest.
- Financial Performance: In its first quarter, Trulieve reported $100 million in adjusted EBITDA, while Tilray expects EBITDA between $62 million and $72 million for the year, highlighting Trulieve's superior profitability.
- Market Competition: Trulieve and Tilray now compete directly on major exchanges; although Tilray has a broader international presence, Trulieve's vertically integrated model provides better resilience against price fluctuations in the U.S. market.
- Tax Relief: With the U.S. rescheduling medical marijuana to Schedule III, Trulieve stands to benefit from reduced 280E tax burdens, significantly improving its financial outlook and reinforcing its market position.
See More
Trulieve Lists on NYSE, Competes with Tilray
- Listing Achievement: Trulieve began trading on the NYSE on June 10, becoming the first U.S. cannabis company to list on a major exchange, marking a significant milestone for the U.S. cannabis industry and potentially attracting more investor interest.
- Financial Performance Comparison: Trulieve reported $100 million in adjusted EBITDA for Q1, while Tilray expects EBITDA between $62 million and $72 million this year, highlighting Trulieve's clear advantage in profitability.
- Market Competition Landscape: With 240 dispensaries, Trulieve's operational model allows it to capture the entire retail markup, whereas Tilray, primarily a wholesale manufacturer, faces greater pricing pressure, resulting in significantly lower profit margins compared to Trulieve.
- Tax Policy Impact: The U.S. reclassification of medical marijuana to Schedule III alleviates Trulieve's 280E tax burden, which is expected to yield substantial financial benefits, further solidifying its leadership position in the market.
See More
Tilray Launches ARX Premium Medical Cannabis Brand in Germany
- Brand Launch: Tilray is set to introduce the ARX brand in Germany, marking its first premium medical cannabis brand aimed at meeting the growing demand for medicinal flower in the country, representing a significant milestone for the company in the German market.
- Local Cultivation: The medicinal flower for the ARX brand will be cultivated at the Aphria RX facility in Neumünster, utilizing strains sourced from Canada, ensuring that product quality meets the needs of patients and healthcare professionals.
- Market Strategy: The decision to launch a premium medical cannabis offering is strategic, aimed at increasing profits by tapping into the high-margin product category in Europe’s largest cannabis market, leveraging Tilray's existing expertise in the field.
- Market Sentiment: Retail sentiment regarding TLRY stock has remained 'extremely bullish' over the past 24 hours, with the stock gaining over 26% in the past 12 months, outperforming the benchmark S&P index, although it still lags behind popular cannabis ETF AdvisorShares Pure US Cannabis ETF.
See More
BrewDog Partners with Tilray to Launch American Craft Beers in the UK
- Market Expansion Strategy: BrewDog's collaboration with Tilray to launch 24 American craft beers marks Tilray's debut in the UK market, expected to rapidly enhance brand visibility through BrewDog's channels and further expand its market share in Europe.
- Consumer Appeal: Initial research indicates that over 50% of beer drinkers find the new brands either very appealing or somewhat appealing, particularly among consumers aged 18-34, highlighting significant demand potential for American craft beers.
- Product Diversity: The launch features a variety of styles, including Sweetwater's fruity IPAs and Montauk's Summer Ale, catering to diverse consumer taste preferences and likely strengthening BrewDog's central role in craft beer culture.
- Promotional Activities: BrewDog will offer U.S. beer flight packages at £12.95 in its bars, supported by high-energy promotions tied to summer sports events, which is expected to attract more consumers to experience American craft beers and drive sales growth.
See More
Tilray Reports 73% Revenue Growth in International Cannabis Business
- Revenue Growth Highlight: Tilray reported $206.7 million in sales for Q3 2026, marking a 73% increase, yet its international cannabis segment only contributes 12% to total sales, indicating a still limited market share.
- Ongoing Loss Risk: Despite revenue growth, Tilray has consistently lost money since going public, with a market cap around $600 million, suggesting that this stock remains a high-risk investment suitable only for aggressive investors.
- Business Transformation Strategy: Tilray is undergoing a significant business overhaul, shifting from a pure-play cannabis company to a global lifestyle and consumer packaged goods firm, though this strategy's sustainability remains to be seen.
- Market Challenges and Opportunities: While international cannabis sales show strength, a 24% decline in beverage sales and a 20% drop in U.S. operations highlight challenges the company faces, necessitating cautious evaluation of its overall business health.
See More
Tilray Transitions to Brand Management Model
- International Growth: Tilray's international cannabis business reported a 73% revenue increase in Q3 2026, totaling $24 million, which, while only 12% of total sales, indicates potential in international markets.
- Overall Sales Performance: The company generated $206.7 million in total sales for the quarter, a significant figure, yet with a market cap of approximately $600 million, it remains a small player, highlighting its fragile market position.
- Ongoing Losses: Tilray has consistently reported losses since going public, and despite its business model shift, the high-risk nature of the stock suggests that most investors should approach with caution until profitability is achieved.
- Transformation Challenges: The shift from a pure cannabis business to a global lifestyle and consumer packaged goods company has seen some successes, yet the beverage segment experienced a 24% sales decline, underscoring the uncertainties and challenges in the transformation process.
See More
Trulieve Becomes First U.S. Cannabis Company Listed on NYSE
- Historic Listing: Trulieve successfully listed on the NYSE on June 10, becoming the first U.S. cannabis company on a major exchange, marking a significant milestone for the U.S. cannabis industry and likely attracting increased investor interest.
- Financial Performance: In its first quarter, Trulieve reported $100 million in adjusted EBITDA, while Tilray expects EBITDA between $62 million and $72 million for the year, highlighting Trulieve's superior profitability.
- Market Competition: Trulieve and Tilray now compete directly on major exchanges; although Tilray has a broader international presence, Trulieve's vertically integrated model provides better resilience against price fluctuations in the U.S. market.
- Tax Relief: With the U.S. rescheduling medical marijuana to Schedule III, Trulieve stands to benefit from reduced 280E tax burdens, significantly improving its financial outlook and reinforcing its market position.
See More
Trulieve Lists on NYSE, Competes with Tilray
- Listing Achievement: Trulieve began trading on the NYSE on June 10, becoming the first U.S. cannabis company to list on a major exchange, marking a significant milestone for the U.S. cannabis industry and potentially attracting more investor interest.
- Financial Performance Comparison: Trulieve reported $100 million in adjusted EBITDA for Q1, while Tilray expects EBITDA between $62 million and $72 million this year, highlighting Trulieve's clear advantage in profitability.
- Market Competition Landscape: With 240 dispensaries, Trulieve's operational model allows it to capture the entire retail markup, whereas Tilray, primarily a wholesale manufacturer, faces greater pricing pressure, resulting in significantly lower profit margins compared to Trulieve.
- Tax Policy Impact: The U.S. reclassification of medical marijuana to Schedule III alleviates Trulieve's 280E tax burden, which is expected to yield substantial financial benefits, further solidifying its leadership position in the market.
See More
Tilray Launches ARX Premium Medical Cannabis Brand in Germany
- Brand Launch: Tilray is set to introduce the ARX brand in Germany, marking its first premium medical cannabis brand aimed at meeting the growing demand for medicinal flower in the country, representing a significant milestone for the company in the German market.
- Local Cultivation: The medicinal flower for the ARX brand will be cultivated at the Aphria RX facility in Neumünster, utilizing strains sourced from Canada, ensuring that product quality meets the needs of patients and healthcare professionals.
- Market Strategy: The decision to launch a premium medical cannabis offering is strategic, aimed at increasing profits by tapping into the high-margin product category in Europe’s largest cannabis market, leveraging Tilray's existing expertise in the field.
- Market Sentiment: Retail sentiment regarding TLRY stock has remained 'extremely bullish' over the past 24 hours, with the stock gaining over 26% in the past 12 months, outperforming the benchmark S&P index, although it still lags behind popular cannabis ETF AdvisorShares Pure US Cannabis ETF.
See More
BrewDog Partners with Tilray to Launch American Craft Beers in the UK
- Market Expansion Strategy: BrewDog's collaboration with Tilray to launch 24 American craft beers marks Tilray's debut in the UK market, expected to rapidly enhance brand visibility through BrewDog's channels and further expand its market share in Europe.
- Consumer Appeal: Initial research indicates that over 50% of beer drinkers find the new brands either very appealing or somewhat appealing, particularly among consumers aged 18-34, highlighting significant demand potential for American craft beers.
- Product Diversity: The launch features a variety of styles, including Sweetwater's fruity IPAs and Montauk's Summer Ale, catering to diverse consumer taste preferences and likely strengthening BrewDog's central role in craft beer culture.
- Promotional Activities: BrewDog will offer U.S. beer flight packages at £12.95 in its bars, supported by high-energy promotions tied to summer sports events, which is expected to attract more consumers to experience American craft beers and drive sales growth.
See More
